Stockholders overwhelmingly approved liquidation and dissolution of the Company
at the June 5, 2025 Annual Meeting
Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025
THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation
Company initiating a sale process of THB335
